

Laurence Camoin-Jau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9422530/publications.pdf>

Version: 2024-02-01

71
papers

3,134
citations

304602

22
h-index

155592

55
g-index

81
all docs

81
docs citations

81
times ranked

3825
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1404-1411.	1.2	531
2	Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis. <i>American Journal of Cardiology</i> , 2009, 103, 5-10.	0.7	271
3	Ticagrelor Increases Adenosine Plasma Concentration in Patients With an Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2014, 63, 872-877.	1.2	247
4	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. <i>Travel Medicine and Infectious Disease</i> , 2020, 36, 101791.	1.5	209
5	High On-Treatment Platelet Reactivity After Prasugrel Loading Dose and Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2011, 58, 467-473.	1.2	196
6	Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2008, 101, 1088-1093.	0.7	194
7	Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. <i>Blood</i> , 2007, 110, 2432-2439.	0.6	181
8	Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis. <i>Thrombosis and Haemostasis</i> , 2010, 104, 456-463.	1.8	153
9	Clopidogrel Loading Dose Adjustment According to Platelet Reactivity Monitoring in Patients Carrying the 2C19*2 Loss of Function Polymorphism. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1630-1636.	1.2	110
10	Natural history of COVID-19 and therapeutic options. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1159-1184.	1.3	101
11	High levels of circulating leukocyte microparticles are associated with better outcome in acute respiratory distress syndrome. <i>Critical Care</i> , 2011, 15, R31.	2.5	80
12	Relation of Body Mass Index to High On-Treatment Platelet Reactivity and of Failed Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2009, 104, 1511-1515.	0.7	78
13	TRAIL/Apo2L Mediates the Release of Procoagulant Endothelial Microparticles Induced by Thrombin In Vitro. <i>Circulation Research</i> , 2009, 104, 943-951.	2.0	72
14	Heparin-Induced Thrombocytopenia in Severe COVID-19. <i>Circulation</i> , 2020, 142, 1875-1877.	1.6	62
15	Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , 2010, 126, e147-e149.	0.8	37
16	Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2560-2570.	1.1	36
17	Comparison Between ESC and Duke Criteria for the Diagnosis of Prosthetic Valve Infective Endocarditis. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2605-2615.	2.3	35
18	Rate of Nuisance Bleedings and Impact on Compliance to Prasugrel in Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2011, 108, 1710-1713.	0.7	34

#	ARTICLE	IF	CITATIONS
19	Intracranial haemorrhage in infective endocarditis. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 712-721.	0.7	33
20	Coronary events complicating infective endocarditis. <i>Heart</i> , 2017, 103, 1906-1910.	1.2	28
21	Level of Adenosine Diphosphate Receptor P2Y12 Blockade During Percutaneous Coronary Intervention Predicts the Extent of Endothelial Injury, Assessed by Circulating Endothelial Cell Measurement. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1024-1031.	1.2	27
22	Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy. <i>Platelets</i> , 2010, 21, 503-507.	1.1	27
23	Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2012, 108, 101-106.	1.8	22
24	Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 1063.	0.5	21
25	Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients. <i>Thrombosis Research</i> , 2010, 125, e167-e170.	0.8	20
26	Soluble MHC Class I chain-related molecule serum levels are predictive markers of implantation failure and successful term pregnancies following IVF. <i>Human Reproduction</i> , 2007, 22, 2261-2266.	0.4	19
27	Thrombosis and antiphospholipid antibody syndrome during acute Q fever. <i>Medicine (United States)</i> , 2017, 96, e7578.	0.4	19
28	Aspirin Effect on Staphylococcus aureusâ€™ Platelet Interactions During Infectious Endocarditis. <i>Frontiers in Medicine</i> , 2019, 6, 217.	1.2	19
29	Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2015, 114, 702-707.	1.8	18
30	Antiplatelet Agents Have a Distinct Efficacy on Platelet Aggregation Induced by Infectious Bacteria. <i>Frontiers in Pharmacology</i> , 2020, 11, 863.	1.6	17
31	Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity. <i>Thrombosis and Haemostasis</i> , 2010, 104, 410-411.	1.8	14
32	A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity. <i>International Journal of Cardiology</i> , 2013, 168, 4244-4248.	0.8	14
33	Spondylodiscitis complicating infective endocarditis. <i>Heart</i> , 2020, 106, 1914-1918.	1.2	13
34	Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. <i>Thrombosis Research</i> , 2012, 130, 70-74.	0.8	12
35	Different pattern of the second outbreak of COVID-19 in Marseille, France. <i>International Journal of Infectious Diseases</i> , 2021, 102, 17-19.	1.5	12
36	¹⁸ F-fluorodeoxyglucose positron emission tomography/computed tomography for the diagnosis of native valve infective endocarditis: A prospective study. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 211-220.	0.7	12

#	ARTICLE	IF	CITATIONS
37	Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2âžł loss of function polymorphism. <i>International Journal of Cardiology</i> , 2010, 145, 165-166.	0.8	11
38	Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes. <i>International Journal of Cardiology</i> , 2016, 220, 496-500.	0.8	11
39	Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting. <i>Frontiers in Medicine</i> , 2020, 7, 599626.	1.2	11
40	Infective endocarditis with neurological complications: Delaying cardiac surgery is associated with worse outcome. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 527-536.	0.7	10
41	Effect of antiplatelet agents on platelet antistaphylococcal capacity: An in vitro study. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105890.	1.1	9
42	A Novel Approach for Detecting Unique Variations among Infectious Bacterial Species in Endocarditic Cardiac Valve Vegetation. <i>Cells</i> , 2020, 9, 1899.	1.8	9
43	Single or triple positivity for antiphospholipid antibodies in âœœcarriersâœœ or symptomatic patients: Untangling the knot. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3018-3030.	1.9	9
44	The distinct effects of aspirin on platelet aggregation induced by infectious bacteria. <i>Platelets</i> , 2020, 31, 1028-1038.	1.1	8
45	Statins potentiate the antibacterial effect of platelets on <i>Staphylococcus aureus</i> . <i>Platelets</i> , 2021, 32, 671-676.	1.1	8
46	Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 465-473.	1.9	7
47	Platelets and <i>Escherichia coli</i> : A Complex Interaction. <i>Biomedicines</i> , 2022, 10, 1636.	1.4	6
48	Comparing two blood culture systems for the detection of bacterial contamination in platelet concentrates. <i>Transfusion</i> , 2018, 58, 2604-2610.	0.8	5
49	Clinical validation of immunoassay HemosILÂ® AcuStar HIT-IgG (PF4-H) in the diagnosis of Heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 601-609.	1.0	5
50	Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 37-45.	1.5	5
51	Case series of massive direct oral anticoagulant ingestionâœœ Treatment and pharmacokinetics data. <i>European Journal of Clinical Investigation</i> , 2022, , e13746.	1.7	5
52	Enhanced Prevalence of Plasmatic Soluble MHC Class I Chain-Related Molecule in Vascular Pregnancy Diseases. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	4
53	Ultrastructure of a late-stage bacterial endocarditis valve vegetation. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 821-826.	1.0	4
54	The Antibacterial Effect of Platelets on <i>Escherichia coli</i> Strains. <i>Biomedicines</i> , 2022, 10, 1533.	1.4	4

#	ARTICLE	IF	CITATIONS
55	Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome. <i>Platelets</i> , 2019, 30, 105-111.	1.1	3
56	Impact of Platelet Reactivity in ACS Patients on Clinical Outcomes with Triple Antithrombotic Therapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 1565.	1.0	3
57	In vitro detection of bacterial contamination in platelet concentrates by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry: a preliminary study. <i>Journal of Medical Microbiology</i> , 2017, 66, 1523-1530.	0.7	3
58	Platelets and endothelium: Two key players in percutaneous coronary intervention. <i>Archives of Cardiovascular Diseases</i> , 2011, 104, 601-603.	0.7	2
59	Tailoring Antiplatelet Therapy: A Step Toward Individualized Therapy to Improve Clinical Outcome?. <i>Current Pharmaceutical Design</i> , 2012, 18, 5392-5401.	0.9	2
60	Platelet Reactivity. <i>Journal of the American College of Cardiology</i> , 2017, 69, 114.	1.2	2
61	Cross-Reactivity Between Heparin and Danaparoid Antibodies in Cardiac Surgery. <i>Annals of Thoracic Surgery</i> , 2017, 103, e9-e10.	0.7	2
62	Rapid identification of microorganisms from platelet concentrates by matrix-assisted laser desorption ionization time-of-flight mass spectrometry after short-term incubation on liquid medium. <i>Transfusion</i> , 2018, 58, 766-773.	0.8	2
63	Drug Response Diversity: A Hidden Bacterium?. <i>Journal of Personalized Medicine</i> , 2021, 11, 345.	1.1	2
64	Mitral valve repair is better than mitral valve replacement in native mitral valve endocarditis: Results from a prospective matched cohort. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 160-168.	0.7	2
65	Personalized antiplatelet therapy for coronary artery disease patients: is this the future?. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1525-1532.	0.6	1
66	Latest Evidence in Personalized Antiplatelet Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Hospital Practice (1995)</i> , 2012, 40, 104-117.	0.5	1
67	Factor VIII:C levels in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. <i>International Journal of Gynecology and Obstetrics</i> , 2012, 116, 258-259.	1.0	1
68	Biological efficacy and clinical safety of a second 600 mg loading dose of clopidogrel in elderly patients with high on-treatment platelet reactivity: A pilot study. <i>International Journal of Cardiology</i> , 2013, 165, 200-201.	0.8	1
69	A threshold of platelet reactivity for ischaemic events?. <i>European Heart Journal</i> , 2008, 29, 2185-2186.	1.0	0
70	TCT-737 Relationship between post treatment platelet reactivity and ischemic and bleeding events at one year follow-up in acute coronary syndrome patients receiving prasugrel. <i>Journal of the American College of Cardiology</i> , 2012, 60, B215.	1.2	0
71	The hidden side of oral thrombin inhibitors. <i>International Journal of Cardiology</i> , 2019, 274, 186-187.	0.8	0